Statin use improves limb salvage after intervention for peripheral arterial disease.

Autor:	Parmar GM; Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala. Electronic address: gparmar@uabmc.edu., Novak Z; Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala., Spangler E; Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala., Patterson M; Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala., Passman MA; Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala., Beck AW; Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala., Pearce BJ; Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala.
Jazyk:	angličtina
Zdroj:	Journal of vascular surgery [J Vasc Surg] 2019 Aug; Vol. 70 (2), pp. 539-546. Date of Electronic Publication: 2019 Feb 02.
DOI:	10.1016/j.jvs.2018.07.089
Abstrakt:	Background: Statin use is recommended in all patients with peripheral arterial disease (PAD) owing to its morbidity and mortality benefits. However, the effect of statin use on limb salvage in patients with PAD after intervention is unclear. We examined the effect of statin use on limb salvage and survival among patients with PAD undergoing surgical or endovascular intervention. Methods: A total of 488 patients with PAD were identified who underwent surgical (n = 297) or endovascular (n = 191) intervention between 2009 and 2010. Information was collected from electronic medical records and the Social Security Death Index. Predictors of ongoing statin use were identified first by univariate analysis and then via multivariable logistic regression. Survival and freedom from amputation were identified using Kaplan-Meier plots and adjusted hazard ratios by Cox regression. Results: Of the 488 patients with PAD with intervention, 39% were non-whites, 44% were females, 41% received statins, 56% received antiplatelets, 26% received oral anticoagulants, 9% required a major amputation, and 11% died during follow-up of up to 88 months. Statin users were more often male (P = .03), white (P = .03), smokers (P < .01), and had higher comorbidities such as coronary artery disease (P < .01), hypertension (P < .01), and diabetes (P < .01). Antiplatelet use was not associated with limb salvage (P = .13), but did improve survival (P < .01). Dual antiplatelet therapy did not show any benefit over monotherapy for limb salvage (P = .4) or survival (P = .3). Statin use was associated with improved survival (P = .04), and improved limb salvage (hazard ratio, 0.3; 95% confidence interval, 0.1-0.7) after adjusting for severity of disease, traditional risk factors, and concurrent antiplatelet use. Conclusions: Statin use in patients with PAD with interventions was associated with improved limb salvage and survival. Despite existing guidelines, statin therapy was low in our PAD population, and efforts are ongoing to increase their use across the health care system. (Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu